Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $383,400.00 in Stock

Key Points

• CEO Nikhil Lalwani sold 5,400 ANI Pharmaceuticals shares at an average price of $71, generating $383,400. The transaction occurred under a pre-arranged Rule 10b5-1 plan, leaving him with 339,089 shares.
• ANI Pharmaceuticals shares recently traded at $73.59, while the company reported quarterly EPS of $2.21 and revenue of $266.04 million, exceeding analyst expectations and marking 25.8% year-over-year revenue growth.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $105.57, although ratings include both Buy and Hold recommendations. Institutional investors own approximately 76.05% of the company.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the firm's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $71.00, for a total value of $383,400.00. Following the sale, the chief executive officer directly owned 339,089 shares of the company's stock, valued at $24,075,319. This represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

• On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP traded up $1.48 during trading hours on Wednesday, hitting $73.59. The company had a trading volume of 431,593 shares, compared to its average volume of 377,903. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of 15.86 and a beta of 0.45. The business has a fifty day moving average of $76.69 and a 200-day moving average of $78.14. ANI Pharmaceuticals, Inc. has a 12 month low of $69.58 and a 12 month high of $98.55. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals's quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ANIP. The Manufacturers Life Insurance Company raised its position in ANI Pharmaceuticals by 1.5% in the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company's stock valued at $736,000 after purchasing an additional 143 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in shares of ANI Pharmaceuticals by 5.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company's stock valued at $323,000 after acquiring an additional 200 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company's stock valued at $48,000 after acquiring an additional 249 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of ANI Pharmaceuticals by 8.0% during the fourth quarter. ProShare Advisors LLC now owns 4,520 shares of the specialty pharmaceutical company's stock worth $357,000 after purchasing an additional 336 shares during the period. Finally, New York State Teachers Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 1.6% during the first quarter. New York State Teachers Retirement System now owns 23,268 shares of the specialty pharmaceutical company's stock worth $1,789,000 after purchasing an additional 356 shares during the period. Institutional investors own 76.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price objective on the stock. Canaccord Genuity Group dropped their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a report on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Finally, Guggenheim lowered their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $105.57.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.